Cover Image

Angiotensin : from the kidney to coronavirus /

Angiotensin: From the Kidney to Coronavirus, a new volume in the Molecular Mediators in Health and Disease series, presents the communication role of the hormone in both health and disease states. Beyond the most common conditions, the book also explores the role of Angiotensin in infectious disease...

Full description

Bibliographic Details
Corporate Author: ScienceDirect (Online service)
Other Authors: Pilowsky, P. M. (Paul M.)
Format: eBook
Language:English
Published: London ; San Diego, CA : Academic Press, an imprint of Elsevier, [2023]
Series:Molecular mediators in health and disease
Subjects:
Angiotensins.
Angiotensins
Angiotensines.
Electronic books.
Online Access:Connect to the full text of this electronic book
Table of Contents:
  • Front Cover
  • Angiotensin
  • Molecular Mediators in Health and Disease: How Cells Communicate Angiotensin: From the Kidney to Coronavirus
  • Copyright
  • Contents
  • List of contributors
  • Preface
  • REFERENCES
  • 1
  • Regulation of sympathetic nerve activity by the central angiotensin system in heart failure
  • 1. Introduction
  • 2. Heart failure results in an increase in resting levels of sympathetic nerve activity
  • 2.1 Consequence of increased sympathetic nerve activity during heart failure
  • 3. Role of angiotensin II
  • 3.1 Circulating levels of angiotensin II in heart failure
  • 3.2 Role of central angiotensinergic mechanisms
  • 3.3 Blockade of central angiotensin type 1 receptor decreases SNA
  • 3.4 Central regions that respond to angiotensin II
  • 3.4.1 The role of the paraventricular nucleus of the hypothalamus in heart failure
  • 3.4.2 Actions of angiotensin II within the rostral ventral lateral medulla
  • 3.4.3 Actions of Ang II within the area postrema
  • 4. Actions of angiotensin II within the spinal cord
  • 4.1 AT1R within the spinal cord
  • 4.2 Regulation of sympathetic nerve activity by AT1R within the spinal cord
  • 4.3 Changes in spinal cord AT1R during heart failure
  • 5. Conclusions
  • 6. Future directions
  • References
  • 2
  • The contribution of angiotensin peptides to cardiovascular neuroregulation in health and disease
  • 1. Introduction
  • 2. The overview of renin-angiotensin system organization: cooperation of central and systemic renin-angiotensin system
  • 3. Cooperation of the brain renin-angiotensin system with the autonomic nervous system: interactions with the sympathetic, par ...
  • 4. Role of the brain renin-angiotensin system in the regulation of water-electrolyte balance
  • 4.1 Regulation of sodium and water intake
  • 4.2 Kidney and gastrointestinal system.
  • 5. Other effects of the brain renin-angiotension system affecting the cardiovascular regulation: role of renin-angiotension sy ...
  • 5.1 Stress and depression
  • 5.2 COVID-19
  • 6. Role of the brain renin-angiotensin system in cardiovascular regulation in hypertension
  • 7. Role of brain renin-angiotensin in cardiovascular regulation in heart failure
  • 8. Renin-angiotension system in diabetes mellitus and metabolic syndrome
  • 9. Renin-angiotensin system in pathogenesis and outcome of myocardial infarction
  • 9.1 Renin-angiotensin system and the atherosclerotic plaque
  • 9.2 Renin-angiotensin system in outcome of myocardial infarction
  • 10. Novel therapeutic perspectives of brain targeting renin-angiotensin system inhibitors in cardiovascular diseases
  • 10.1 ACE inhibitors
  • 10.2 Angiotensin receptor blockers
  • 11. Conclusions and perspectives
  • References
  • 3
  • Renin-angiotensin system and inflammation
  • 1. Introduction
  • 2. The classic renin-angiotensin system axis
  • 2.1 Renin
  • 2.1.1 Renin role in inflammation
  • 2.2 Angiotensin-converting enzyme
  • 2.2.1 Angiotensin-converting enzyme role in inflammation
  • 2.3 Angiotensin II
  • 2.3.1 Angiotensin type 1 receptor
  • 2.3.1.1 Angiotensin II type 1 receptor role in inflammation
  • 2.3.1.1 Angiotensin II type 1 receptor role in inflammation
  • 2.3.2 Angiotensin type 2 receptors
  • 2.3.2.1 Angiotensin II type 2 receptors role in inflammation
  • 2.3.2.1 Angiotensin II type 2 receptors role in inflammation
  • 3. The counterregulatory renin-angiotensin system axis
  • 3.1 Angiotensin-converting enzyme 2
  • 3.1.1 ACE2 role in inflammation
  • 3.2 Angiotensin-(1-7)
  • 3.3 Mas receptor
  • 3.3.1 Angiotensin-(1-7) and Mas receptor role in inflammation
  • 4. Other renin-angiotensin system mediators
  • 4.1 Alamandine
  • 4.2 Ang-(1-9)
  • 5. Evidence in human diseases.
  • 6. Future directions and perspectives
  • References
  • 4
  • Targeting renin-angiotensin system: a strategy for drug development against neurological disorders
  • 1. Introduction
  • 2. Renin-angiotensin system in brain
  • 3. Drug development strategies targeting renin-angiotensin system
  • 3.1 MasR agonists
  • 4. ACE2 activators
  • 5. AT2R agonists
  • 6. ACE inhibitors
  • 7. AT1R blockers
  • 8. Renin inhibitors
  • 9. Conclusion
  • References
  • 5
  • Pharmacology of angiotensin in renovascular diseases
  • 1. Introduction
  • 2. RAAS in the glomerulus and tubular region: physiological and pathological considerations
  • 3. Renovascular hypertension
  • 3.1 Pathophysiology of renovascular hypertension
  • 3.2 Role of angiotensin II in renovascular hypertension
  • 3.3 AT2 receptor activation in renovascular hypertension
  • 4. Atheromatous renovascular disease
  • 4.1 Pathophysiology of ARVD
  • 4.2 Angiotensin II in progression of ARVD
  • 4.3 Role of ACE-I/ARBs (ACE inhibitors/angiotensin receptor blockers) in ARVD
  • 5. Ischemic renovascular disease
  • 5.1 Pathophysiology
  • 5.2 Role of Angiotensin II in ischemia nephropathy
  • 6. Diabetic nephropathy
  • 6.1 Pathogenesis of diabetic nephropathy
  • 6.2 Role of angiotensin II, ACE inhibitors, and ARBs in diabetic nephropathy
  • 7. Conclusion
  • 8. Conflict of interest
  • References
  • 6
  • The role of angiotensins in the pathophysiology of human pregnancy
  • 1. Introduction
  • 2. The renin-angiotensin system
  • 3. The circulating renin-angiotensin-aldosterone system in normal pregnancy
  • 3.1 Changes in components of the RAAS in human pregnancy
  • 4. The intrarenal RAS in pregnancy
  • 5. The intrauterine renin-angiotensin system: placenta, fetal membranes, and decidua
  • 5.1 RAS components in the placenta in normal pregnancy
  • 5.1.1 Effects of fetal sex, gestation, and labor on the expression of the placental RAS.
  • 5.2 RAS components in the intrauterine membranes in normal pregnancy
  • 5.2.1 Effects of gestation and labor on the expression of the RAS in fetal membranes
  • 5.3 RAS components in the decidua in normal pregnancy
  • 5.3.1 Effects of fetal sex, gestation, and labor on the expression of the RAS in fetal membranes
  • 6. The RAS and hypertension in pregnancy
  • 7. The role of the RAS in regulating fetal growth
  • 7.1 Changes in the maternal circulating RAAS in pregnancies associated with FGR
  • 7.2 Changes in placental RAS expression in pregnancies associated with FGR
  • 8. The RAS in gestational diabetes
  • 9. Conclusions
  • References
  • 7
  • Hematopoietic bone marrow renin-angiotensin system in health and disease
  • 1. Introduction
  • 2. Local bone marrow renin-angiotensin system in hematopoiesis
  • 3. Local bone marrow renin-angiotensin system in neoplastic hematopoiesis
  • 4. Local bone marrow renin-angiotensin system in atherosclerosis
  • 5. Local bone marrow renin-angiotensin system in hypertension
  • 6. Local bone marrow renin-angiotensin system and COVID-19 syndrome
  • 7. Conclusion and perspectives
  • References
  • 8
  • Angiotensin II as a mediator of renal fibrogenesis
  • 1. Introduction
  • 2. The intrarenal renin-angiotensin system
  • 2.1 "Classical" actions of Ang II in the kidney
  • 3. The renal renin-angiotensin system: much more complex than previously thought
  • 3.1 Ang II and renal growth
  • 3.2 Ang II and renal inflammation
  • 3.3 Ang II and renal fibrosis
  • 4. Conclusion and future directions
  • References
  • Further reading
  • 9
  • Angiotensin and atherosclerotic vascular disease
  • 1. The global burden of the atherosclerotic vascular disease
  • 2. Endothelial dysfunction
  • 3. The renin-angiotensin system
  • 4. The role of angiotensin in the pathophysiology of atherosclerotic plaques.
  • 5. Interaction between angiotensin and other mediators of the atherosclerotic process
  • 6. Angiotensin-clinical and therapeutical implications
  • References
  • 10
  • ACE2 in pulmonary diseases
  • 1. Introduction
  • 2. ACE2 and pulmonary hypertension
  • 3. ACE2 and asthma
  • 4. ACE2 and pulmonary fibrosis
  • 5. ACE2 and lung cancer
  • 6. ACE2 and chronic obstructive pulmonary disease
  • 7. ACE2 and acute lung injury
  • 8. ACE2 and COVID-19
  • 9. Role of ACE2 in lung repair and regeneration
  • References
  • 11
  • Renin-angiotensin-aldosterone system inhibitors. New and old approaches
  • 1. Introduction
  • 2. Why new drugs for hypertension
  • 2.1 Renin
  • 2.1.1 Angiotensinogen
  • 2.1.2 Blocking the activity of the ACE/Ang II/AT1-R
  • 2.1.3 Potentiating the opposing function of the ACE2/Ang-(1-7)/Mas-R axis
  • 3. Perspective
  • References
  • 12
  • Aspects of the intracellular renin-angiotensin system
  • 1. Introduction
  • 2. Kidney
  • 3. Heart
  • 4. Brain
  • 5. Intracellular RAS ligands
  • 6. Summary
  • References
  • 13
  • Interactions between the renin-angiotensin-aldosterone system and COVID-19: pharmacological interventions
  • 1. Introduction
  • 1.1 The physiology of the renin-angiotensin-aldosterone system
  • 1.2 The renin-angiotensin-aldosterone system and SARS-CoV-2
  • 2. Renin-angiotensin-aldosterone system therapeutic venues in the context of SARS-CoV-2 infection
  • 2.1 Direct renin inhibitor
  • 2.2 ACEIs/ARBs
  • 2.3 Aldosterone inhibitors (spironolactone)
  • 2.4 Beta-blockers
  • 2.5 Heparin
  • 2.6 Glucocorticoids
  • 3. Perspectives
  • References
  • 14
  • Angiotensin II and its action within the brain during hypertension
  • List of abbreviations
  • 1. Introduction
  • 2. Hypertension and angiotensin II
  • 3. Angiotensin II increases blood-brain barrier disruption in hypertension.